<SEC-DOCUMENT>0001193125-20-289235.txt : 20201109
<SEC-HEADER>0001193125-20-289235.hdr.sgml : 20201109
<ACCEPTANCE-DATETIME>20201109172419
ACCESSION NUMBER:		0001193125-20-289235
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20201109
DATE AS OF CHANGE:		20201109

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MICROVISION, INC.
		CENTRAL INDEX KEY:			0000065770
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTRONIC COMPONENTS, NEC [3679]
		IRS NUMBER:				911600822
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-228113
		FILM NUMBER:		201298816

	BUSINESS ADDRESS:	
		STREET 1:		6244 185TH AVENUE NE, SUITE 100
		CITY:			REDMOND
		STATE:			WA
		ZIP:			98052
		BUSINESS PHONE:		425-936-6847

	MAIL ADDRESS:	
		STREET 1:		6244 185TH AVENUE NE, SUITE 100
		CITY:			REDMOND
		STATE:			WA
		ZIP:			98052

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MICROVISION INC
		DATE OF NAME CHANGE:	19960724
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d801444d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(5) <BR> Registration No. 333-228113 </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(To Prospectus dated November&nbsp;13, 2018) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g801444g45q33.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>MicroVision, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>$10,000,000 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common
Stock </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into a sales agreement with Craig-Hallum Capital Group LLC, or Craig-Hallum, relating to the sale of up to $10,000,000 of shares of our common
stock, $0.001 par value per share. Subject to the terms and conditions of the Sales Agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $10,000,000 from time to time through Craig-Hallum, as our
agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our shares are quoted on The NASDAQ Global Market under the symbol &#147;MVIS.&#148; On November&nbsp;3, 2020, the last reported sale price of our
common stock on The NASDAQ Global Market was $1.84 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sales of our common stock, if any, under this prospectus supplement and the accompanying
prospectus may be made in sales deemed to be &#147;at the market&#148; equity offerings as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, or the Securities Act, including sales made directly on or through The NASDAQ
Global Market, the existing trading market for our common stock, sales made to or through a market maker other than on an exchange or otherwise, in negotiated transactions at market prices prevailing at the time of sale or at prices related to such
prevailing market prices, and/or any other method permitted by law. Craig-Hallum is not required to sell a certain number of shares or dollar amount of our common stock. Craig-Hallum will use commercially reasonable efforts to sell on our behalf all
of the shares of common stock requested to be sold by us, consistent with their normal trading and sales practices, on mutually agreed terms between Craig-Hallum and us. There is no arrangement for funds to be received in any escrow, trust or
similar arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Craig-Hallum will be entitled to a commission equal to 2.35% of the gross sales price per share sold under the sales agreement. In
connection with the sale of the common stock on our behalf, Craig-Hallum may be deemed to be an &#147;underwriter&#148; within the meaning of the Securities Act, and the compensation of Craig-Hallum may be deemed to be underwriting commissions or
discounts. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our common stock involves a high degree of risk. Please see the section entitled &#147;<A HREF="#supptoc801444_3">Risk Factors</A>&#148;
beginning on page <FONT STYLE="white-space:nowrap">S-4</FONT> of this prospectus supplement, for a discussion of important risks that you should consider before making an investment decision. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or determined if this
prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Craig-Hallum Capital Group </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus supplement is November&nbsp;9, 2020 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prospectus Supplement </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">Page</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc801444_1">PROSPECTUS SUPPLEMENT SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc801444_2">NOTE REGARDING FORWARD-LOOKING STATEMENTS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc801444_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc801444_4">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc801444_5">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc801444_6">DESCRIPTION OF SECURITIES WE ARE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc801444_7">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-8</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc801444_8">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-10</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc801444_9">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-10</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc801444_10">DOCUMENTS INCORPORATED BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-10</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prospectus </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B></B>Page<B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca801444_1">NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca801444_2">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca801444_3">THE COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca801444_4">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca801444_5">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca801444_6">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca801444_7">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca801444_8">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca801444_9">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca801444_10">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca801444_11">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement is not complete without, and may not be utilized except in connection with, the accompanying prospectus dated November&nbsp;13,
2018 and any amendments thereto. This prospectus supplement provides supplemental information regarding the Company, updates and changes information contained in the accompanying prospectus and describes the specific terms of this offering. The
accompanying prospectus gives more general information, some of which may not apply to this offering. We incorporate by reference important information into this prospectus supplement and the accompanying prospectus. You may obtain the information
incorporated by reference into this prospectus supplement and the accompanying prospectus without charge by following the instructions under &#147;Where You Can Find More Information&#148; in the accompanying prospectus. You should carefully read
both this prospectus supplement and the accompanying prospectus, as well as additional information described under &#147;Documents Incorporated by Reference,&#148; before deciding to invest in shares of our common stock. If the information in, or
incorporated by reference in, this prospectus supplement conflicts with information in the accompanying prospectus or a document incorporated by reference herein or therein, the information in, or incorporated by reference in, this prospectus
supplement shall control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All references in this prospectus supplement to &#147;MicroVision,&#148; &#147;the Company,&#148; &#147;we,&#148;
&#147;us&#148; or &#147;our&#148; mean MicroVision, Inc., unless we state otherwise or the context otherwise requires. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>You should rely only on the
information contained or incorporated by reference in this prospectus supplement and the accompanying prospectus. We have not, and the agent has not, authorized anyone to provide you with different or additional information. If anyone provides you
with different or additional information, you should not rely on it. We are not, and the agent is not, making an offer to sell these securities under any circumstance or in any jurisdiction where the offer is not permitted or unlawful. You should
assume that the information contained in this prospectus supplement and the accompanying prospectus is accurate only as of their respective dates, and that any information in documents that we have incorporated by reference is accurate only as of
the date of the document incorporated by reference. Our business, financial condition, results of operations, cash flows and prospects may have changed since those dates. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc801444_1"></A>PROSPECTUS SUPPLEMENT SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following summary is qualified in its entirety by, and should be read together with, our consolidated financial statements and related notes thereto
and the more detailed information appearing elsewhere or incorporated by reference in this prospectus supplement and the accompanying prospectus. Before you decide to invest in our common stock, you should read the entire prospectus supplement and
the accompanying prospectus carefully, including the risk factors and the financial statements and related notes included or incorporated by reference in this prospectus supplement and the accompanying prospectus. </I></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Our Company </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MicroVision, Inc. is a pioneer in laser beam scanning (LBS) technology that we market under our brand name
PicoP<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. We have developed our proprietary PicoP<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> scanning technology that can be used in products for interactive projection, consumer
light detection and ranging (LiDAR), automotive LiDAR, and augmented and mixed reality. Our PicoP<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> scanning technology is based on our patented expertise in systems that include
micro-electrical mechanical systems (MEMS), laser diodes, opto-mechanics, electronics, algorithms and software and how those elements are packaged into a small form factor, low power scanning engine that can display, interact and sense, depending on
the needs of the application. These systems utilize edge computing and machine intelligence as part of the solutions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the past few years, our growth
strategy has included selling LBS modules designed for original equipment manufacturers (OEMs) and original design manufacturers (ODMs). We planned to offer three scanning modules to support a wide array of applications: an interactive scanning
module for smart home speakers and other Internet of Things (IoT) products, a LiDAR module for consumer electronic applications, and solutions for augmented and mixed reality devices. We have also been developing our 1st generation MEMS Dynamic
Scanning Long Range LiDAR (LRL) module for OEM and Tier 1 acceptance for automotive active collision avoidance systems and autonomous driving vehicles. This product would also be targeted for Direct Sales to Technology companies focused on Mobility
as a Service (MaaS) that continue to drive the market for automotive LiDAR. However, we have so far been unable to secure a customer to launch one of our module products. As a result, we plan to focus our attention on strategic alternatives,
including a potential sale or merger of the Company, sale of part of the Company, strategic minority investment, as well as licensing and other transactions. We currently have no agreements or commitments to engage in any specific strategic
transactions, and our exploration of various strategic alternatives may not result in any specific action or transaction. We may be unable to identify, successfully negotiate with and consummate a suitable transaction with a buyer or other strategic
partner on favorable terms, on the timeline we expect, or at all. If we determine to engage in a strategic transaction, we cannot predict the impact that such a transaction might have on our operations or stock price, and we cannot predict the
impact on our stock price or operations if we fail to enter into such a transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While we continue to pursue strategic alternatives, we plan to focus
on completing development of our 1st Generation LRL module to a level that would be ready to scale in market. We believe our technology and designs for automotive LiDAR can be successful in the market, and our solutions will have features and
performance that exceed those of competitors and will provide a sustainable strategic advantage in the market. These efforts are designed to increase potential shareholder value, including in a potential strategic transaction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were founded in 1993 as a
Washington corporation and reincorporated in 2003 under the laws of the State of Delaware. Our principal office is located at 6244 185th Ave NE, Suite 100, Redmond, WA 98052 and our telephone number is <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">425-936-6847.</FONT></FONT> We maintain a website at www.microvision.com, where general information about us is available. We do not incorporate the information on our website into this prospectus supplement or the
accompanying prospectus and you should not consider it part of this prospectus supplement or the accompanying prospectus. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Offering </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Common stock we are offering</B> </P></TD>
<TD>Shares of our common stock having an aggregate offering price of up to $10&nbsp;million. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Common stock to be outstanding after this offering </B></P></TD>
<TD> Up to 149,340,692 shares, which assumes sales of 5,434,782 shares at an assumed public offering price of $1.84 per share, which was the last reported sale price of our common stock on The NASDAQ Global Market on November&nbsp;3, 2020. The
actual number of shares issued will vary depending on the sales price of shares sold in this offering. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Manner of offering</B> </P></TD>
<TD>&#147;At the market&#148; offering that may be made from time to time through our agent, Craig-Hallum. See &#147;Plan of Distribution&#148; on page <FONT STYLE="white-space:nowrap">S-8.</FONT> </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Use of proceeds</B> </P></TD>
<TD>We currently intend to use the net proceeds from this offering, if any, for general corporate purposes, which may include, but are not limited to, working capital and capital expenditures, as we pursue a potential strategic transaction. See
&#147;Use of Proceeds&#148; on page <FONT STYLE="white-space:nowrap">S-6.</FONT> </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Risk factors</B> </P></TD>
<TD>See &#147;Risk Factors&#148; on page <FONT STYLE="white-space:nowrap">S-4</FONT> of this prospectus supplement and on page 1 of the accompanying prospectus for a discussion of the factors you should carefully consider before deciding to invest
in our common stock. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Listing</B> </P></TD>
<TD>Our common stock is listed on The NASDAQ Global Market under the symbol &#147;MVIS.&#148; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of shares of common stock to be
outstanding after this offering is based on 143,905,910 shares outstanding as of September&nbsp;30, 2020 and excludes, as of that date, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3,905,650 shares of our common stock issuable upon exercise of outstanding options, of which approximately
2,658,333 were exercisable at a weighted average exercise price of $1.78 per share, under our 2020 Incentive Plan, as amended; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,001,112 shares of our common stock underlying unvested stock awards; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3,080,987 shares of our common stock reserved for issuance pursuant to our 2020 Incentive Plan.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of shares outstanding shown above does not reflect any issuances of shares following September&nbsp;30, 2020, including
2.5&nbsp;million shares of our common stock issued to Lincoln Park Capital Fund, LLC (&#147;Lincoln Park&#148;) during the fourth quarter of 2020 under a prior Common Stock Purchase Agreement that we entered into with Lincoln Park in December 2019.
The number of shares of our common stock reserved for issuance pursuant to our 2020 Incentive Plan shown above does not reflect 5.0&nbsp;million additional shares registered to be offered pursuant to the 2020 Incentive Plan on October&nbsp;9, 2020.
</P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc801444_2"></A>NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus and the documents incorporated by reference herein and therein contain forward-looking statements,
within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and is subject to the safe harbor created by those
sections. Such statements may include, but are not limited to, projections of revenues, income or loss, capital expenditures, plans for product development and our cooperative arrangements, future operations, financing needs or plans, as well as
assumptions relating to the foregoing. The words &#147;anticipate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;goal,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;project,&#148; and similar expressions identify
forward-looking statements, which speak only as of the date the statement was made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These forward-looking statements may include those relating to
amounts sold under the Sales Agreement and the use of proceeds therefrom, the value of our technology, timing of products coming to market, management of finances, exploration of strategic alternatives with third parties and the Company&#146;s
future products and product applications are forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Factors that could cause
actual results to differ materially from those projected in such forward-looking statements include the risk that the Company may not succeed in finding licensing or other strategic solutions, including a potential sale of the Company, with
acceptable timing, benefits or costs; our ability to operate with limited cash or to raise additional capital when needed; market acceptance of our technologies and products or for products incorporating our technologies; the failure of our
commercial partners to perform as expected under our agreements, including from the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> (coronavirus); our ability to identify parties interested in paying any amounts or amounts we deem
desirable for the purchase or license of intellectual property assets; our or our customers&#146; failure to perform under open purchase orders; our financial and technical resources relative to those of our competitors; our ability to keep up with
rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards and develop partnership
opportunities; the timing of commercial product launches and delays in product development; the ability to achieve key technical milestones in key products; dependence on third parties to develop, manufacture, sell and market our products; potential
product liability claims; our ability to maintain our listing on The Nasdaq Stock Market; and other risk factors identified from time to time in the Company&#146;s SEC reports, including the Company&#146;s Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> filed with the SEC. These factors are not intended to represent a complete list of the general or specific factors that may affect us. It should be recognized that other factors, including general economic
factors and business strategies, may be significant, now or in the future, and the factors set forth in this release may affect us to a greater extent than indicated. Except as expressly required by federal securities laws, we undertake no
obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changes in circumstances or any other reason. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc801444_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>An investment in our securities involves a high degree of risk. You should carefully consider all of the information in this prospectus supplement and the
accompanying prospectus, including the risks and uncertainties described below, and all other information included or incorporated by reference in this prospectus supplement and the accompanying prospectus, before you decide whether to purchase our
securities. The risks and uncertainties we describe are not the only ones facing us. Additional risks not presently known to us or that we currently deem immaterial may also impair our business operations. If any of these risks were to occur, our
business, financial condition or results of operations would likely suffer. In that event, the trading price of our common stock could decline and you could lose all or part of your investment. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to our Common Stock and this Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We have broad discretion in the use of the net proceeds from this offering and may not use them effectively.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our management will have broad discretion in the application of the net proceeds from this offering and could spend the proceeds in ways that do not
necessarily improve our results of operations or enhance the value of our common stock. Our failure to apply these funds effectively could have a material adverse effect on our business, financial condition, operating results and cash flow, and
could cause the price of our common stock to decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>If you purchase the common stock sold in this offering, you will experience immediate and
substantial dilution in your investment. You will experience further dilution if we issue additional equity securities in future fundraising transactions. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since the price per share of our common stock being offered is substantially higher than the net tangible book value per share of our common stock, you will
suffer substantial dilution with respect to the net tangible book value of the common stock you purchase in this offering. Based on an assumed public offering price of $1.84 per share, the last reported sale price of our common stock on
November&nbsp;3, 2020 on The NASDAQ Global Market, and our net tangible book value as of September&nbsp;30, 2020, if you purchase shares of common stock in this offering, you will suffer immediate and substantial dilution of $1.80 per share with
respect to the net tangible book value of the common stock. See the section entitled &#147;Dilution&#148; elsewhere in this prospectus supplement for a more detailed discussion of the dilution you will incur if you purchase common stock in this
offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are generally not restricted from issuing additional common stock, including any securities that are convertible into or exchangeable for,
or that represent the right to receive, common stock. If we issue additional common stock, or securities convertible into or exchangeable or exercisable for common stock, our stockholders, including investors who purchase shares of common stock in
this offering, could experience additional dilution, and any such issuances may result in downward pressure on the price of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Future
sales of shares by existing stockholders could cause our stock price to decline. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sales of a substantial number of shares of our common stock in the
public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2020, we had outstanding options to purchase an aggregate of 3,905,650 shares of our common stock, of which approximately 2,658,333
were exercisable at a weighted average exercise price of $1.78 per share. The exercise of such outstanding options will result in further dilution of your investment. If our existing stockholders sell substantial amounts of our common stock in the
public market, or if the public perceives that such sales could occur, this could have an adverse impact on the market price of our common stock, even if there is no relationship between such sales and the performance of our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We do not currently intend to pay dividends on our common stock, and any return to investors is expected
to come, if at all, only from potential increases in the price of our common stock. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the present time, we intend to use available funds to finance
our operations. Accordingly, while payment of dividends rests within the discretion of our board of directors, no cash dividends on our common shares have been declared or paid by us and we have no intention of paying any such dividends in the
foreseeable future. Any return to investors is expected to come, if at all, only from potential increases in the price of our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc801444_4"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will retain broad discretion over the use of the net proceeds from the sale of our common stock offered hereby. Except as described in any free writing
prospectus that we may authorize to be provided to you, we currently anticipate that the net proceeds from the sale of the securities offered under this prospectus supplement will be used for general corporate purposes, which may include, but are
not limited to, working capital and capital expenditures, as we pursue a potential strategic transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pending the application of the net proceeds, we
expect to invest the proceeds in investment-grade, interest-bearing instruments or other securities. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc801444_5"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you invest in our common stock, your interest will be diluted by an amount equal to the difference between the public offering price and the net tangible
book value per share of common stock after this offering. We calculate net tangible book value per share by dividing our net tangible book value (total assets less intangible assets and total liabilities) by the number of outstanding shares of
common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our net tangible book value at September&nbsp;30, 2020 was $(4,371,000), or $(0.03) per share of common stock. After giving effect to the
sale of shares of our common stock in the aggregate amount of $10,000,000 at an assumed offering price of $1.84 per share, the last reported sale price of our common stock on November&nbsp;3, 2020 on The NASDAQ Global Market, and after deducting
estimated commissions and estimated offering expenses, our <FONT STYLE="white-space:nowrap">as-adjusted</FONT> net tangible book value at September&nbsp;30, 2020 would have been $5,261,000, or $0.04 per share. This represents an immediate increase
in <FONT STYLE="white-space:nowrap">as-adjusted</FONT> net tangible book value of $0.07 per share to existing shareholders and an immediate and substantial dilution of $1.80 per share to new investors. The following table illustrates this per share
dilution: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net tangible book value per share at September&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.03)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in net tangible book value per share attributable to this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">As-adjusted</FONT> net tangible book value per share as of
September&nbsp;30, 2020, after giving effect to this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table above assumes, for illustrative purposes only, that an aggregate of 5,434,782 shares of our common stock are sold at
an assumed offering price of $1.84 per share, for aggregate gross proceeds of approximately $10,000,000. The shares sold in this offering, if any, will be sold from time to time at various prices. An increase of $0.50 per share in the price at which
the shares are sold from the assumed offering price of $1.84 per share shown in the table above, assuming all of our common stock in the aggregate amount of $10,000,000 is sold at that price, would not change our
<FONT STYLE="white-space:nowrap">as-adjusted</FONT> net tangible book value per share after the offering but would increase the dilution in net tangible book value per share to new investors in this offering to $2.30 per share, after deducting
commissions and estimated aggregate offering expenses payable by us. A decrease of $0.50 per share in the price at which the shares are sold from the assumed offering price of $1.84 per share shown in the table above, assuming all of our common
stock in the aggregate amount of $10,000,000 is sold at that price, would not change our <FONT STYLE="white-space:nowrap">as-adjusted</FONT> net tangible book value per share after the offering but would decrease the dilution in net tangible book
value per share to new investors in this offering to $1.31 per share, after deducting commissions and estimated aggregate offering expenses payable by us. This information is supplied for illustrative purposes only. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that any options are exercised, new options are issued under our 2020 Incentive Plan or we otherwise issue additional shares of common stock in
the future, there will be further dilution to new investors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These calculations are based on 143,905,910 shares outstanding as of September&nbsp;30, 2020 and exclude, as
of that date, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3,905,650 shares of our common stock issuable upon exercise of outstanding options, of which approximately
2,658,333 were exercisable at a weighted average exercise price of $1.78 per share, under our 2020 Incentive Plan, as amended; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,001,112 shares of our common stock underlying unvested stock awards; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3,080,987 shares of our common stock reserved for issuance pursuant to our 2020 Incentive Plan.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of shares outstanding shown above does not reflect any issuances of shares following September&nbsp;30, 2020, including
2.5&nbsp;million shares of our common stock issued to Lincoln Park during the fourth quarter of 2020 under a prior Common Stock Purchase Agreement that we entered into with Lincoln Park in December 2019. The number of shares of our common stock
reserved for issuance pursuant to our 2020 Incentive Plan shown above does not reflect 5.0&nbsp;million additional shares registered to be offered pursuant to the 2020 Incentive Plan on October&nbsp;9, 2020. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc801444_6"></A>DESCRIPTION OF SECURITIES WE ARE OFFERING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are offering up to $10,000,000 of shares of our common stock. The material terms and provisions of our common stock are described under the caption
&#147;Description of Capital Stock&#148; starting on page 2 of the accompanying prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc801444_7"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into the Sales Agreement with Craig-Hallum under which we may offer and sell up to $10,000,000 of our shares of common stock, par value $0.001
from time to time through Craig-Hallum acting as agent. Sales of our shares of common stock, if any, under this prospectus supplement and the accompanying base prospectus will be made by any method that is deemed to be an &#147;at the market
offering&#148; as defined in Rule 415(a)(4) under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each time we wish to issue and sell our shares of common stock under the Sales
Agreement, we will notify Craig-Hallum of the number of shares to be issued, the dates on which such sales are anticipated to be made, any limitation on the number of shares to be sold in any one day and any minimum price below which sales may not
be made. Once we have so instructed Craig-Hallum, unless Craig-Hallum declines to accept the terms of such notice, Craig-Hallum has agreed to use its commercially reasonable efforts consistent with its normal trading and sales practices to sell such
shares up to the amount specified on such terms. The obligations of Craig-Hallum under the Sales Agreement to sell our shares of common stock are subject to a number of conditions that we must meet. Craig-Hallum may engage in passive market making
transactions in the shares of common stock on The NASDAQ Global Market in accordance with Regulation M under the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The settlement of sales of
shares between us and Craig-Hallum is generally anticipated to occur on the second trading day following the date on which the sale was made. Sales of our shares of common stock as contemplated in this prospectus supplement will be settled through
the facilities of The Depository Trust Company or by such other means as we and Craig-Hallum may agree upon. There is no arrangement for funds to be received in an escrow, trust or similar arrangement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will pay Craig-Hallum a commission equal to 2.35% of the aggregate gross proceeds we receive from each sale of our shares of common stock sold pursuant to
the Sales Agreement. Because there is no minimum offering amount required as a condition to close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. In addition, we have
agreed to reimburse Craig-Hallum for all reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> accountable fees and disbursements in an amount not to exceed $50,000. We estimate that the total
expenses for the offering, excluding any commissions or expense reimbursement payable to Craig-Hallum under the terms of the Sales Agreement, will be approximately $50,000. The remaining sale proceeds, after deducting any other transaction fees,
will equal our net proceeds from the sale of such shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Craig-Hallum will provide written confirmation to us no later than the open of trading on The
NASDAQ Global Market on the trading day immediately following each trading day on which our shares of common stock are sold under the Sales Agreement. Each confirmation will include the number of shares sold on that day, the price or prices at which
such shares were sold, the aggregate gross proceeds of such sales, the proceeds to us and the commission payable to Craig-Hallum with respect to such sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the sale of our shares of common stock on our behalf, Craig-Hallum will be deemed to be an &#147;underwriter&#148; within the meaning of
the Securities Act, and the compensation of Craig-Hallum will be deemed to be underwriting commissions or discounts. We have agreed to indemnify Craig-Hallum against certain civil liabilities, including liabilities under the Securities Act. We have
also agreed to contribute to payments Craig-Hallum may be required to make in respect of such liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The offering of our shares of common stock
pursuant to the Sales Agreement will terminate upon the earlier of (i)&nbsp;the sale of all shares of common stock subject to the Sales Agreement and (ii)&nbsp;the termination of the Sales Agreement as permitted therein. We and Craig-Hallum may each
terminate the Sales Agreement at any time by giving written notice, provided that such termination will not be effective until the close of business on the date specified in such notice received by Craig-Hallum or us, as the case may be, in
accordance with the Sales Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This summary of the material provisions of the Sales Agreement does not purport to be a complete statement
of its terms and conditions. A copy of the Sales Agreement is filed as an exhibit to a current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed under the Exchange Act on November&nbsp;9, 2020 and is incorporated by reference in this
prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any portion of the $10,000,000 included in this prospectus supplement that is not previously sold or included in an active
issuance notice pursuant to the Sales Agreement is available for sale in other offerings pursuant to the accompanying base prospectus, and if no shares are sold under the Sales Agreement, the full $10,000,000 of securities may be sold in other
offerings pursuant to the accompanying base prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The NASDAQ Global Market and trades under the symbol
&#147;MVIS.&#148; The transfer agent of our common stock is American Stock Transfer&nbsp;&amp; Trust Company, LLC, located at 6201 15th Avenue, Brooklyn, New York. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Craig-Hallum and its affiliates may in the future provide various investment banking, commercial banking, financial advisory and other financial services for
us and our affiliates, for which services they may in the future receive customary fees. In the course of its business, Craig-Hallum may actively trade our securities for its own account or for the accounts of customers, and, accordingly,
Craig-Hallum may at any time hold long or short positions in such securities. Craig-Hallum has performed, is currently performing and may in the future perform, various financial advisory and investment banking services for us in connection with our
evaluation of potential strategic transactions, for which they received or will receive customary fees and expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A prospectus supplement and the
accompanying base prospectus in electronic format may be made available on a website maintained by Craig-Hallum, and Craig-Hallum may distribute the prospectus supplement and the accompanying prospectus electronically. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Offer restrictions outside the United States </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other than
in the United States, no action has been taken by us or Craig-Hallum that would permit a public offering of the securities offered by this prospectus supplement in any jurisdiction where action for that purpose is required. The securities offered by
this prospectus supplement and the accompanying base prospectus may not be offered or sold, directly or indirectly, nor may this prospectus supplement or any other offering material or advertisements in connection with the offer and sale of any such
securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus supplement comes are
advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus supplement. This prospectus supplement does not constitute an offer to sell or a solicitation of an offer to buy any
securities offered by this prospectus supplement in any jurisdiction in which such an offer or a solicitation is unlawful. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc801444_8"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The validity of the common stock being offered hereby will be passed upon by Ropes&nbsp;&amp; Gray LLP, Boston, Massachusetts. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc801444_9"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our consolidated financial statements appearing in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31,
2019, and the effectiveness of our internal control over financial reporting as of December&nbsp;31, 2019, have been audited by Moss Adams LLP, an independent registered public accounting firm, as stated in their reports, which are incorporated
herein by reference. Such consolidated financial statements have been so incorporated in reliance upon the report of such firm (which report expresses an unqualified opinion and includes explanatory paragraphs relating to a going concern uncertainty
and a change in the method of accounting for leases) given upon their authority as experts in accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc801444_10">
</A>DOCUMENTS INCORPORATED BY REFERENCE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and special reports, proxy statements and other information with the Securities and
Exchange Commission, or the SEC. These documents are on file with the SEC. Our SEC filings are also available to the public from the SEC&#146;s website at www.sec.gov. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus are part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> including
amendments, relating to the common stock offered by this prospectus supplement and the accompanying prospectus, which have been filed with the SEC. This prospectus supplement and the accompanying prospectus do not contain all of the information set
forth in the registration statement and the exhibits and schedules thereto, certain parts of which are omitted in accordance with the rules and regulations of the SEC. Statements contained in this prospectus supplement and the accompanying
prospectus as to the contents of any contract or other document referred to are not necessarily complete and in each instance reference is made to the copy of that contract or other document filed as an exhibit to the registration statement. For
further information about us and the common stock offered by this prospectus supplement and the accompanying prospectus we refer you to the registration statement and the exhibits and schedules which may be obtained as described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; the information contained in documents that we file with them, which means that we can disclose
important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus supplement and the accompanying prospectus. Information in the accompanying prospectus supersedes
information incorporated by reference that we filed with the SEC before the date of the prospectus, and information in this prospectus supplement supersedes information incorporated by reference that we filed with the SEC before the date of this
prospectus supplement, while information that we file later with the SEC will automatically update and supersede the information in this prospectus supplement and the accompanying prospectus or incorporated by reference. We incorporate by reference
the documents listed below and any future filings we will make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the time that all securities covered by this prospectus supplement have been sold; provided, however,
that we are not incorporating any information furnished under any of Item 2.02 or Item 7.01 of any current report on Form <FONT STYLE="white-space:nowrap">8-K:</FONT> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/65770/000113626120000079/body10k.htm">Form <FONT
STYLE="white-space:nowrap">10-K</FONT></A> for the fiscal year ended December&nbsp;31, 2019 filed with the SEC on March&nbsp;12, 2020; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The information specifically incorporated by reference into our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2019 from our Definitive Proxy Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/65770/000119312520098166/d875853ddef14a.htm">Schedule 14A</A> filed with
the SEC on April&nbsp;3, 2020; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarterly periods ended
March&nbsp;31, 2020, June&nbsp;30, 2020, and September&nbsp;30, 2020 filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/65770/000113626120000116/form10q.htm">May&nbsp;
8, 2020</A>,<A HREF="http://www.sec.gov/Archives/edgar/data/65770/000113626120000149/form10q.htm"> June&nbsp;30, 2020</A>, and <A HREF="http://www.sec.gov/Archives/edgar/data/65770/000113626120000174/form10q.htm">October&nbsp;30, 2020</A>,
respectively; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/65770/000117184320002510/f8k_040920.htm">April&nbsp;9,
 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/65770/000117184320002775/f8k_042220.htm">April&nbsp;22, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/65770/000117184320002933/f8k_042820.htm">April&nbsp;
28, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/65770/000119312520148686/d909162d8k.htm">May&nbsp;21, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/65770/000117184320003947/f8k_052120.htm">May&nbsp;
22, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/65770/000117184320004163/f8k_060420.htm">June&nbsp;4, 2020</A>, and <A HREF="http://www.sec.gov/Archives/edgar/data/65770/000119312520267210/d56666d8k.htm">October&nbsp;9, 2020</A>.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will promptly provide, without charge to each person (including any beneficial owners) who receives a copy of this prospectus, upon
written or oral request, a copy of any or all of the documents incorporated by reference in this prospectus supplement. Requests should be directed to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MicroVision, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6244 185th
Avenue NE, Suite 100 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Redmond, Washington 98052 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: Investor Relations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(425) <FONT STYLE="white-space:nowrap">936-6847</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You can also find these filings on our website at www.microvision.com. We are not incorporating the information on our website other than these filings into
this prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>$60,000,000 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>MicroVision, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Preferred
Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell
from time to time up to $60,000,000 of our common stock, preferred stock, or warrants in one or more transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will provide
specific terms of these securities and offerings in supplements to this prospectus. You should read this prospectus and any supplement carefully before you invest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is traded on The Nasdaq Global Market under the symbol &#147;MVIS.&#148; On November&nbsp;9, 2018, the closing price of our
common stock on The Nasdaq Global Market was $1.02 per share. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>The
securities offered in this prospectus involve a high degree of risk. You should carefully consider the information under the heading &#147;<A HREF="#toca801444_2">Risk Factors</A>&#148; set forth herein on page 1 and in our filings made with the
Securities and Exchange Commission, which are incorporated by reference in this prospectus, in determining whether to purchase our securities. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our executive offices are located at 6244 185<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>&nbsp;Avenue NE, Suite 100, Redmond,
Washington 98052, and our telephone number is <FONT STYLE="white-space:nowrap">(425)&nbsp;936-6847.</FONT> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the
Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is November&nbsp;13, 2018. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B></B>Page<B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca801444_1">NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca801444_2">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca801444_3">THE COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca801444_4">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca801444_5">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca801444_6">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca801444_7">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca801444_8">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca801444_9">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca801444_10">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca801444_11">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca801444_1"></A>NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and the documents incorporated by reference in this prospectus contain forward-looking statements, within the meaning of
Section&nbsp;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and is subject to the safe harbor created by those sections. Such
statements may include, but are not limited to, projections of revenues, income or loss, capital expenditures, plans for product development and cooperative arrangements, future operations, financing needs or plans of MicroVision, as well as
assumptions relating to the foregoing. The words &#147;anticipate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;goal,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;project,&#148; &#147;will,&#148; and similar
expressions identify forward-looking statements, which speak only as of the date the statement was made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These forward-looking statements
are not guarantees of future performance. Factors that could cause actual results to differ materially from those projected in our forward-looking statements include the following: our ability to raise additional capital when needed; market
acceptance of our technologies and products, and for products incorporating our technologies; the failure of our commercial partners to perform as expected under our agreements; our ability to identify parties interested in paying any amounts or
amounts we deem desirable for the purchase or license of intellectual property assets; our or our customers&#146; failure to perform under open purchase orders; our financial and technical resources relative to those of our competitors; our ability
to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards and to develop
partnership opportunities; the timing of commercial product launches and delays in product development; the ability to achieve key technical milestones in key products; dependence on third parties to develop, manufacture, sell and market our
products; potential product liability claims; and other factors set forth in the section entitled &#147;Risk Factors&#148; below, and in the documents incorporated by reference into this prospectus. These factors are not intended to represent a
complete list of the general or specific factors that may affect us. It should be recognized that other factors, including general economic factors and business strategies, may be significant, now or in the future, and the factors set forth in this
prospectus may affect us to a greater extent than indicated. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth in or incorporated into
this prospectus. Except as required by law, we undertake no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca801444_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should carefully consider the specific risks set forth under the caption &#147;Risk Factors&#148; in our most recent annual report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> and quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> each as amended or supplemented, which are incorporated by reference in this prospectus, as the same may be amended, supplemented
or superseded by our subsequent quarterly or annual reports or other filings, including filings after the date hereof, with the Securities and Exchange Commission under the Exchange Act. The risks and uncertainties we describe are not the only ones
facing us. Additional risks not presently known to us or that we currently deem immaterial may also impair our business operations. If any of these risks were to occur, our business, financial condition or results of operations would likely suffer.
In that event, the trading price of our common stock could decline, and you could lose all or part of your investment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca801444_3"></A>THE COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MicroVision, Inc. is a pioneer in laser beam scanning (LBS) technology that we market under our brand name PicoP<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. We have developed our proprietary PicoP<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;scanning technology that can be adopted by our customers to create high-resolution
miniature projection and three-dimensional sensing and image capture solutions. PicoP<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;scanning technology is based on our patented expertise in micro-electrical mechanical systems
(MEMS), laser diodes, opto-mechanics, and electronics and how those elements are packaged into a small form factor, low power scanning engine that can display, interact and sense, depending on the needs of the application. For display, the engine
can project a high-quality image on any surface for use in pico projection and augmented or virtual reality. For sensing, we use infrared (IR) lasers to capture three-dimensional data in the form of a point cloud. Interactivity uses the 3D sensing
function and the display function to project an image that the user could then interact with as one would a touch screen. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our strategy
includes selling LBS engines to original design manufacturers (ODMs) and original equipment manufacturers (OEMs). We plan to offer three scanning engines to support a wide array of applications: a small form factor display engine for consumer
products, an interactive scanning engine for smart Internet of Things (IoT) products, and a light detection and ranging (LiDAR) engine for consumer electronic applications. We also are developing LiDAR for automotive collision avoidance systems.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to selling modules, we have licensed our patented
PicoP<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;scanning technology to other companies for incorporation into their scanning engines for projection. We sell our licensees key components needed to produce their laser scanning
engines and/or license our technology in exchange for a royalty fee for each scanning engine they sell. Companies to whom we license our PicoP<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;scanning technology are typically ODMs or
OEMs who are in the business of making components or products ready for sale to end users. To date, we have primarily focused on the consumer electronics market, however, we believe that our LBS technology creates a platform that could support
multiple applications and markets including medical, industrial and automotive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we are optimistic about our technology and the
potential for future revenues, we have incurred substantial losses since inception and we expect to incur a significant loss during the fiscal year ending December&nbsp;31, 2018. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca801444_4"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in the applicable prospectus supplement, we anticipate that the net proceeds from the sale of the securities
offered under this prospectus will be used for general corporate purposes, which may include, but are not limited to, working capital and capital expenditures. The prospectus supplement relating to specific sales of our securities hereunder will set
forth our intended use for the net proceeds we receive from the sales. Pending the application of the net proceeds, we expect to invest the proceeds in investment-grade, interest-bearing instruments or other securities. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca801444_5"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Certificate of Incorporation, as amended, authorizes us to issue 150,000,000 shares of common stock, $0.001 par value per share, and
25,000,000 shares of preferred stock, $0.001 par value per share. As of October&nbsp;30, 2018, there were 93,073,343 shares of common stock, and no shares of preferred stock, outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Common Stock.</I>&nbsp;All outstanding common stock is, and any stock issued under this prospectus will be, duly authorized, fully paid and
nonassessable. Subject to the rights of the holders of our outstanding preferred stock, holders of common stock: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">are entitled to any dividends validly declared; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">will share ratably in our net assets in the event of a liquidation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">are entitled to one vote per share. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The common stock has no conversion rights. Holders of common stock have no preemption,
subscription, redemption, or call rights related to those shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">American Stock Transfer&nbsp;&amp; Trust Company is the transfer agent
and registrar for our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Preferred Stock.</I>&nbsp;The Board of Directors has the authority, without further action by the
shareholders, to issue shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof, including dividend rights, conversion rights, voting rights, terms of redemption, liquidation
preferences, sinking fund terms and the number of shares constituting any series or the designation of such series. The issuance of preferred stock could adversely affect the voting power of holders of our common stock and the likelihood that such
holders will receive dividend payments and payments upon liquidation may have the effect of delaying, deferring or preventing a change in control of MicroVision, which could depress the market price of our common stock. If we offer preferred stock,
the terms of that series of preferred stock will be set forth in the prospectus supplement relating to that series. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca801444_6">
</A>DESCRIPTION OF WARRANTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue warrants for the purchase of common stock, preferred stock, warrants or units of any
combination of the foregoing securities. Each series of warrants will be issued under a warrant agreement all as set forth in the prospectus supplement or term sheet relating to the warrants offered hereby. A copy of the form of warrant agreement,
including any form of warrant certificates representing the warrants, reflecting the provisions to be included in the warrant agreements and/or warrant certificates that will be entered into with respect to particular offerings of warrants, will be
filed as an exhibit to a Form <FONT STYLE="white-space:nowrap">8-K</FONT> to be incorporated into the registration statement of which this prospectus forms a part prior to the issuance of any warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement or term sheet will describe the terms of the warrants offered thereby, any warrant agreement relating to
such warrants and the warrant certificates, including but not limited to the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the offering price or prices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the aggregate amount of securities that may be purchased upon exercise of such warrants and minimum number of
warrants that are exercisable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of securities, if any, with which such warrants are being offered and the number of such warrants
being offered with each security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date on and after which such warrants and the related securities, if any, will be transferable separately;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount of securities purchasable upon exercise of each warrant and the price at which the securities may be
purchased upon such exercise, and events or conditions under which the amount of securities may be subject to adjustment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date on which the right to exercise such warrants shall commence and the date on which such right shall
expire; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the circumstances, if any, which will cause the warrants to be deemed to be automatically exercised;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any material risk factors, if any, relating to such warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the identity of any warrant agent; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other terms of such warrants. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the exercise of any warrants, holders of such warrants will not have any rights of holders of the securities purchasable upon such
exercise, including the right to receive payments of dividends, if any, on the securities purchasable upon such exercise, statutory appraisal rights or the right to vote such underlying securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prospective purchasers of warrants should be aware that material U.S. federal income tax,
accounting and other considerations may be applicable to instruments such as warrants. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca801444_7"></A>PLAN OF DISTRIBUTION
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>General.</I>&nbsp;We may sell the securities offered hereby directly to one or more purchasers, through agents, or through
underwriters or dealers designated from time to time. The distribution of securities may be effected from time to time in one or more transactions at a fixed price or prices (which may be changed from time to time), at market prices prevailing at
the times of sale, at prices related to these prevailing market prices or at negotiated prices. The applicable prospectus supplement will describe the terms of the offering of the securities, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of the securities to which such prospectus supplement relates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the name or names of any underwriters, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purchase price of the securities and the proceeds we will receive from the sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any underwriting discounts and other items constituting underwriters&#146; compensation; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any discounts or concessions allowed or reallowed or paid to dealers. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Underwriters named in the prospectus supplement, if any, are only underwriters of the securities offered with the prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Sales Directly to Purchasers.</I>&nbsp;We may enter into agreements directly with one or more purchasers. Such agreements may provide for
the sale of securities at a fixed price, based on the market price of the securities or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Use of Underwriters and Agents</I>.
If underwriters are used in the sale of securities, they will acquire the securities for their own accounts and may resell them from time to time in one or more transactions at a fixed public offering price or at varying prices determined at the
time of sale. The securities may be offered to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Subject to certain conditions, the underwriters will be obligated to purchase all
the securities offered by the prospectus supplement. Any public offering price and any discounts or concessions allowed or reallowed or paid to dealers may change from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Securities may be sold directly to or through agents from time to time. Any agent involved in the offering and sale of securities will be
named and any commissions paid to the agent will be described in the prospectus supplement. Unless the prospectus supplement states otherwise, any agent will act on a best-efforts basis for the period of its appointment. Agents or underwriters may
be authorized to solicit offers by certain types of institutional investors to purchase securities at the public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a
specified date in the future. The conditions to these contracts and the commissions paid for solicitation of these contracts will be described in the prospectus supplement. We may engage in &#147;at the market&#148; offerings only of our common
stock. An &#147;at the market&#148; offering is defined in Rule 415(a)(4) under the Securities Act, as an offering of equity securities into an existing trading market for outstanding shares of the same class at other than a fixed price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Deemed Underwriters.</I>&nbsp;In connection with the sale of the securities offered with this prospectus, underwriters, dealers or agents
may receive compensation from us or from purchasers of the securities for whom they may act as agents, in the form of discounts, concessions or commissions. The underwriters, dealers or agents which participate in the distribution of the securities
may be deemed to be underwriters under the Securities Act and any discounts or commissions received by them and any profit on the resale of the securities received by them may be deemed to be underwriting discounts and commissions under the
Securities Act. Anyone deemed to be an underwriter under the Securities Act may be subject to statutory liabilities, including Sections 11, 12 and 17 of the Securities Act and Rule <FONT STYLE="white-space:nowrap">10b-5</FONT> under the Exchange
Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Indemnification and Other Relationships</I>. We may provide agents and underwriters with
indemnification against certain civil liabilities, including liabilities under the Securities Act, or contribution with respect to payments that the agents or underwriters may make with respect to such liabilities. Agents and underwriters may engage
in transactions with, or perform services for, us in the ordinary course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Listing of Securities.</I>&nbsp;Except as
indicated in the applicable prospectus supplement, the securities offered hereby are not expected to be listed on a securities exchange or market, except for the common stock, which is currently listed on The Nasdaq Global Market, and any
underwriters or dealers will not be obligated to make a market in securities. We cannot predict the activity or liquidity or any trading in the securities. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca801444_8"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and special reports, proxy statements and other information with the SEC. You may read and copy any document we file
at the SEC at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-SEC-0330</FONT></FONT></FONT> for further information. Our SEC
filings are also available to the public from the SEC&#146;s website at http://www.sec.gov. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca801444_9"></A>INCORPORATION OF
CERTAIN INFORMATION BY REFERENCE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; the information we file with them, which
means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus, and the information that we file later with the SEC will
automatically update and supersede this information. We incorporate by reference the documents listed below and any future filings we will make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the time that all
securities covered by this prospectus have been sold; provided, however, that we are not incorporating any information furnished under any of Item&nbsp;2.02 or Item&nbsp;7.01 (including exhibits furnished under Item&nbsp;9.01 in connection with
information furnished under Item&nbsp;2.02 or Item&nbsp;7.01) of any current report on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K:</FONT> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/65770/000113626118000055/body10k.htm">Form <FONT
STYLE="white-space:nowrap">10-K</FONT></A> for the fiscal year ended December&nbsp;31, 2017 filed with the SEC on February&nbsp;23, 2018; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarters ended March&nbsp;31,
2018,&nbsp;June&nbsp;30, 2018 and September&nbsp;30, 2018 filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/65770/000113626118000123/form10q.htm">May&nbsp;10, 2018</A>,&nbsp;
<A HREF="http://www.sec.gov/Archives/edgar/data/65770/000113626118000193/form10q.htm">August&nbsp;1, 2018</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/65770/000113626118000279/form10q.htm">October&nbsp;26, 2018</A>, respectively;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Definitive Proxy Statement on Schedule 14A filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/65770/000119312518124908/d542647ddef14a.htm">April&nbsp;20,
 2018</A>, as amended and supplemented by the additional definitive proxy soliciting materials on Schedule 14A filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/65770/000119312518124926/d542647ddefa14a.htm">April&nbsp;20,
2018</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/65770/000119312518167289/d591252ddefa14a.htm">May&nbsp;18, 2018</A>; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/65770/000119312518164757/d588967d8k.htm">May&nbsp;16,
 2018</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/65770/000119312518186335/d500205d8k.htm">June&nbsp;7, 2018</A>; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The description of our common stock set forth in Amendment No.&nbsp;
1 to our registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/65770/0000912057-96-017869.txt">Form <FONT STYLE="white-space:nowrap">SB-2</FONT></A> (Registration
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">No.&nbsp;333-5276-LA),</FONT></FONT> including any amendment or report filed for the purpose of updating such description, as incorporated by reference in our registration statement
on <A HREF="http://www.sec.gov/Archives/edgar/data/65770/0000912057-96-018347.txt">Form <FONT STYLE="white-space:nowrap">8-A</FONT></A> (Registration <FONT STYLE="white-space:nowrap">No.&nbsp;0-21221).</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also specifically incorporate by reference any documents filed by us with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the
Exchange Act after the date of the initial filing of this registration statement and prior to the effectiveness of this registration statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may request a copy of these filings, at no cost, by writing or telephoning us at the
following address: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MicroVision, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6244 185th Avenue NE, Suite 100 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Redmond, Washington 98052 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: Investor Relations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(425) <FONT STYLE="white-space:nowrap">936-6847</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement that we have filed with the SEC. You should rely only on the information or
representations provided in this prospectus. We have not authorized anyone to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the
information in this prospectus is accurate as of any date other than the date on the front of the document. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca801444_10"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purpose of this offering, Ropes&nbsp;&amp; Gray LLP, Boston, Massachusetts, is giving its opinion on the validity of the securities
offered hereby. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca801444_11"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our consolidated financial statements appearing in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended
December&nbsp;31, 2017, and the effectiveness of our internal control over financial reporting as of December&nbsp;31, 2017, have been audited by Moss Adams LLP, an independent registered public accounting firm, as stated in their report, which is
incorporated herein by reference. Such consolidated financial statements have been so incorporated in reliance upon the report of such firm (which report expresses an unqualified opinion and includes an explanatory paragraph regarding a going
concern emphasis) given upon their authority as experts in accounting and auditing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g801444g45q33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g801444g45q33.jpg
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MMA.,YQP:*$5I%=D8X,$B,:7@A&(38\_"_LQ-8E/M2\.>_O\ 9B2VXE["_?\
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MYL%,]K*"0$NVRXZU&/5DPR0KE@A(=<Q!-BR$/*UY8RK(HTTVGJG1[=P0. .
M. . . . . . . . . . 0.;NURGOOYD]6:RLT?!?KGXN=:5K?MY!2$_:)LW;
M7>3[\S3@(W#5CZ)K5(H-:@[+%O+4M<2:IX9)B*&V)_,D:)^&#WFZZ16O>TN^
MQ/'P9C@&/6^>VG6+JZ)P:[$;]U+IJ&Y'5)AL[!O5?KI8LVCY8RD$ G3FSM@?
MSE"_A%"#B$ISX+^#*O@KV$I-Z)OHK(/=^^<CH)VMKMZZM:(ZY=JO)2Q>!R0-
MJHNA-27H-3C S,QF2Y#M-J+2J;< ]:DR(26R!*'6IP6</1*9G.R C\K#PNH2
MCFW&#6:\35\=*L]VUYL#S:[=KU>KNJ^H?37QU:H#!A=>KL3?VQ[-V#V. J(J
M"P,!M5FC:8Q4ZB+E#QT>*U' V\@/0.8:Q#D-+=:QC(BH*[E*3_\ %4N[N^QE
M1J_I=VIQ<*E?>RWDJ[ ;=GU*R K1'UQJ&@:?ZT:7+/!2<4MBO6L!5:O:=BV^
MJS7HN()448VE]9D4]*@$DNQ)2XZ1#:II12OB[;K;/+SHK_= *4G=GJB/(?N/
MZ?R!&@P&Q8;1#"?FW&MR(NN-$0Q_RQ_9M]X*U>,XSG.,_ 7(;SCW5GV&LLL&
M"W=_=OW+E7!@=%VAKJK[?UIL+4]W@H)TW9U(M6OK8.6E"DSJW<0<ZO&XN<.)
M6CW?&D9+:<J2K"5*PKVS[<$ITTUP=]BJ?Z6/>UFJ@WN7XX=BDU2;'U>VP9M5
M*COK7\V0T^RE:'M$./CN+RJ&(!7ZNBCR6,)5G)389-Q;GR5C&1KBJ_#/_)*^
MM+V]"W5P8C@#@#@#@#@#@#@#@#@#@#@#@'C&K=":ZT_:MV7BH0)_\N[![)1M
M+:!\N0=)D#-BAU*MT0)"C..)0@=7:U4JF$"@ <1"(L%IF7+7]Y$D1F2A+;=)
MZ)4O4AO\@_J*>BO1Z:<U]4"LGM+O8.N3"EZ]U(7'XJ%9+Q\K;6/OVV'6B-="
M26)#;T0@*J\&\681-95%-5\;E6',"\,.4L]%N_9<?3GJ0:4KM]Z@7S7/E)G7
MJ:*Z2]3_ +YS)G;-9=):HI(T5!6ZF>YG=A-HQMF[G!4=N2T71J58L+&DX3_(
M!U>84T^S'S+YKO[&CCA8>MR>V67I6VK?(EAZ?>F?Z0T98O<':2^7'OOM.QLP
M;-*M-WL! ;J@M)G1V9D0R/KH0\1,W2-*9>2K$V\7NVA3D/,:7@%$PO+>9*/%
ME512@MED^_X2+%&NM8:UU!5H%&U/KZDZQI8I/Q&U+7]6!TZM0,?%*,_B Z]!
M'#8ZE)0C"U-1DJ7A*?EG.<8X,CO/ /PZZVPVX\\XAEEE"W7775I;;:;;3E;C
MCCB\X2A"$XRI:U9PE*<9SG.,8SG@%7OTU%27L=GR0]^B,9?Y7;SN7=<UV9*;
M5AZ35:P8LE]=GP5.8SEN!/L&X2 Q]*,I^R75\-.H]H3&<#7%R\$?\8JTN#>O
M?IS+0_!D. 4"_%;L5ND^J&[?5@$_AH3M_=WD(UY*:85A,>5'%7^Z;84TA*,_
M6IA!76++\?XXRC"&491[)]N#HFG_  QOAX7Y52U>S_"HOZ<'.. . . . . .
M . . . . . . 41/4A>:3;+>V[UX[^L5J*Z]I-&C1 G8O8=<F/C;5?K*8%12
M<[5X4Q%6W,"4<".(Q1]R7 =C$;6<64K<QQJL#)D>SCHPL-->*5/9='K^C&?T
MZ/AAUWWAEV/MYV@'ILN@-6W=5*I&J5.N,PMJ;'#CA)XQ*NRF5M27-?5.&;")
MR#C+0W<SDUX>4E(! 3 :Q"<7$:^F.3U;VV2]S89PJG51M7CT<=6:_ I<0&BL
MQ*A"##HM7BUMN%^M;K\>OL1FQ+(- [_3T"6XB8"87^53'PQ_T^#F(/#5NM'A
M8OL.-8&C]O\ $KLNTM0PIMAHA8+%XZ[W:2?P8KA%MI,LF6ZFV@S-PBM/)3(E
MZH*2\5UI+D)X)$LPO7C_ -]LOJ]*EO\ Y=;N<X">!VD('LU9,"[%7+",@&P)
M\&0B%0IL,4BM31A824@NOPB(TA#?9EP9T1]Z-*C.MOL.N-+2K(H<KP# ORC;
MS1UM\=_<;<:9F!Y.M:&O0NL3,N?7B/>+P,50:$OY>Z<YS_-+0!QAM"DN.YS]
M;:DK6E6!:*N45NU?3C]C$#QH6S17C\Z_^/3QO[,-.T'L!MSKO-V^$@'QCPRO
MVW8ED-INVRZ# MDKZH!'80>P74A&@5G*\DI( (SEE#7S$P90F=RE*25J^N7#
MRYZ+)639\%#H^S=AUC4>M]@;6NT] NFZSI5IO]L)+RA*(%;IP.=83<S.5J0C
M_+C1TEW&%+3C.48QG./?WX!K6O3]G['O#SKZJW&5;5DN>-=J]O6O+:ENH9E7
MK4&VV)REN9PG*V_WEVCM)<<3CYK<;SE.%JQ[1M=?-CJQ<L-+_5=MNW V;O).
M4< < < < < < < < < < < < U@_J7^O$[1WE1VG;6H*XM5[&5&B;LK3R6\_
MC+ER@C=$NK&)&,?6N:J[4DZ9E1\YP]'CG8"W$8:DQW'1UX+N%;-KOG[G0O$)
MYO=P^*YRVT%5"'[LZ\;!L+-ML.MI9YVJ'ZW<,CX069<*+9T#342',*!AHJ'8
M I@(0@&VP09,697Y+,F?)$XF'XZ:=-9=5^BT0!]79X]I8QIZR:)[A!"_U85(
M'BJ?IL^/2[G&,J;BE9&[@+\A&%>^,.R!,'*L>V<M)]\XP,?X9[QZV_Q?V,K*
M!Y=;7WG#LU+3?B![K;FT3LQMJL7.R[G!ZDU1K<WKVR92-M+T67?;=/H-Z80"
ME3'55]NVQHA;/P'R"@],K$IL4</#K.-K:WFNBR=[F-ECL.]_3U;":?;'7KL#
MX:-C6K&(H]IV7:=I="+/:"?R4*'RI;[LH_I\D3F*R*B$):6'Y3V(6)XV^NJD
M;:%LL393[>/T2?K?:R1IW<NK.P6MJIN#2M[KNR=:7<8V6K%OJ\]$\62BKRIM
MUI6<81(@$8$A#L$L'),1"X8E'E#"T&$0BR(S0S::=/)HBT\M8'_B'MO0/H0T
MC\L=V:[6AMD;>&+Q\XD_KCU/%JW!M >13[92PR;LG]-@$*3(PJ/DH3B1DM.R
M9#"<"T<E*6RI:ZRR]+?D9,^27H/0_(9UJL&GS\K%3V0 D)O&@MMP?OC6'4>W
MP;2WZO:!A*!E!-@7(E);&6F#!=;>G!)#[L)<4Y!"DQPB,G%WPT:X-<45G>BW
MJ3[QUBLI_IQY;J7<<; TQ9"NLB>_JH+;.6F,2J<]X++B;?J$5QB18WHJH;F6
M=C4;)(A98>8$V952TR7-M4\:RPK2EAYITZV\V_LSI7G?]0%UO[$=6IO4WHI>
MSNP4[DD0&MT;-53;I0Q(77@N4P5>H(2->P=6LL\W;RL4?'L,U@1@)&JD8L$5
M*(OV%U L3A8;4O%)4EHG6;]JUZU1X_Z0KKO.LG9'LOVA(05Y ZLU0*U& EOM
MYQ'>M^U;%"L)!X>[G'LY,!UG7CT2>E"L_CQ;A$RZGWEL*P)QWE&/._9>Y?UX
M.8< < < < < < < < < < < < K;^IF\?9'MQTLB[WUR#<+;CZA/GKVU!@1E
M/E++ILS%AXVL$C-,IPY*EU]D.$V!!0XMU3<"KV,>-C.D#J$.#7"GX94])9='
MP_'Z-:?P=9LI/!EX7^I&A.L>@>U5_I-4WGV.W3K6C;DCWBYCH-GK^L1U_ #K
M=7*YK, 0;E!!)0$(*0(Q>[?CS+-/.)*+%F!H%^*)9')B3E*36B3:KID[WOL6
M5.#(Z];JC5K]5[#2+O70MNIUL#D*]9ZO8QL0P!L (M%<A$Q!@5/:?AD!T^(\
M['E1)++C+S3BD+1G&> 4Z>RG4WN[X ]G6WMYXV7S6X^@%G+KLN]^IUGDF++"
MUA&S\?V!)3#;DDTU68$-&&P6W@7V6FG0HL,7L]BTU88\2-C92CB)*>4EDI;\
MGP[^5-DI_CO\A?C_ /)?V*K':*D;',4GM=7^O9+1#?5K:)8 /)5 ,:NL+8-Y
MM.M6\PX_]095BG P PO9JR5FO,U6L 4&:K3)DLC&("DX2@J:R;NUH]:O;C7'
M-Z\)Z."AK</5<:EI>O/)=7KG5FX40QNWKGK_ &!?H,?#:'W;6&LMYUHP;D--
MX3A"2=4HE:B)6M/V/RA$V0M:U.YSA\^?/UU8#?A:X)Y>K7S<K1C1I$R1@!Q$
M"84+%9L4:+&#HSTT@1(SGVXL*!!AQD.2)<R9)=:CQ8T=MQY]]Q#32%N+2G(V
MTU-LQX9NAN?'GT,U9IJP0H\;;5KS)VSO-YC+3F<;/NT0>N:!5(9^3<A%&KP^
MNT-,AEUR+-=K3Y2-G""&<<'%.7CDWPT71:?GS)4^"@X X X X X X X X X
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M7(>;%U^OPAXJ AZ0ZX^]B-$:^U]QQYSY.+6K(H=TX X X X X X X X X X
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MKK_6%!B*3E3Z5&X@NO32#\9J0X#J:2I]V.J('E82*R@WBN*XN^EJV_GV(/?
M#T=V!Y*N[^R/)GVS;D7&D:UVA-O:)9N+E0O:794I(;L8@=$B._-A-3U'&EC+
M,Z)86W!'3/Z>5V-'E \%H,=\^?,C3$DH14([>:7Y?I?([7ZAR[7#M'YF^L'2
MNAVD^*CBPFA--$(0$M/A*BWC?>P5FRQ-],-]IM'UTJTT)]:WT9Q'CPERG',,
M+]FQ&&DL.4G7';@LM>9\7J>-Z;J#]\-%]<K->ML:=Z<@=5ZUGCXNOU%,B#T,
MO9RL'8U]'5]LY71-]ME0$18U<#@3)N*T.R$CQVI@-%H($9P848N+=)RX)TZK
M3AE;.;ZE^&KQO=WVXD?K?YGMDW6U28JI2];DJW"IFTXR&&<O35*UQ<K8#MTR
M,/PE:9A04+(A4Y1]C)-YA;3S@B4YQUPXK_U==[HR)]14Q'Z#>+OH/T UW?[*
M3D.7R7.F7&3,>%V>Y M.5:>JSDRZ(4QU4=-@O>W =@D1D2GVV94-B.V^ZAE>
M5!A?5.3:54^B;:_9TWNOW)W5XM?!SXV>MFEKF>HG8#M5K"?L&V[$A$)/\]I-
M+L;<';-[CB3#KBR0&WD[!N&OU,=8FG\$ @<-8XX!Z$2C#28H(Q4\23:5)O):
M/@M.2OF<=U$],39NV/7#7/9#M;W+VV V]NZE!]F"Z] "IN;]0$W(<R>JV+E8
M;E9'#5DL4H1.'E; /C8KF1,Z5(!_G3'X3A-YU\A+%IM*,?"F]5KS^(Z'Z=3L
MMV6TEY.MM^.BY;ALVV--#VM[TW]0:-%S=9K]XT:=EL1;W0HYF80?JL _$ &!
MLX2.?8'E6#0V048ED XR3'$XL8N"FDDW3?-25Y[N^)X!OL)MGS->?S;?6%G?
M6P:+J"J7[:6NA)>O3B)@+K>@=>*N5#&IM6J^#(L3E5YO]8=RX0^]M$@M=4EG
MES([+$-0E5#"3I-O/-;O*_+XCQ7RY] ]K^$C9766Y:)[P[BMAC;,?814.4C3
M3.O+O2"FKIE%R])<E@+<2BE@E@3=XK<5IYB$G#@<K#F,$8SV<MB<.2Q+4H1R
MK1;WOFC+C_G,>?#_ ,6JG_QC6?\ \[@R\.'_ )O_ *_DQ\Z$52V]Y?490MVG
MJM8OX1*[4[H[$QBY4(38@C:IK#%NM>HF_P J7&;97B+.":["PW/FG/S4P\A.
M,(PC$6MT:R:CA4M?"DTFLF];^Y[+ZAR7O?I;YF:7V^T7',UJY;%TO4#= OL0
M"^2A+NS5/MN@["-%NY8<@S[4)JD$3(P,SF1*AMEP,R1#=BRXR'Y(PJE!Q>B>
M>=99->5I_<DK\6_3*U>+7Q,=PN_.VZR=&]PMTZ'V!;P@PW G9O%%KF 9'^C]
M*GQI+;AD;9[W?R BZW5A>$$4YF5(6;'LFZE):X*3EXYJ*_I3I<.K\N'+J8,^
MDJT$1#=@.W/9N^ "M=$ZET>!H$$A81,\>TV]LNS/6PV1'XF1FUOOB0FHG&)K
ML5+CL6(;PRY\4D$)<C71EL>2:BDT\[RKAE[^I\WIT:'=>S/F%[2=U-AU2PB&
MQU=WAMN),/")T%<?8'8'8S<&!!:<F,--XRFG'=A,Y3'6KZ6X[;#:/H7G*%IZ
M4^V7S\C%:4(Q5/33DO=OCZYF,NZ<=FO#_P"=G;'<BY=9[QMJCE]_]AMH4R:P
M/.#ZWL77O8G%[6W(JVQ(0"P!HMLK0J_JC%82HLQ^(;$S@Q*%$C34RT.K)7AQ
M,-1\2322SW7LUQ_%%B3J%ZCL=V[[+:=ZVU_H=O"F$]M6UBM_RX_;QSP6K0&X
M4PL:L!)E-.AKDQ P<=/(.1T28RY.(^&4/-*<PK"UNNYE+#<4VY1=<$[>VR\R
M&3?54L_>OU2]2"/UP]-UOJSL!KD W+EAR&0**UU1I<6^7<=)(NQ\0,CC5WI-
MRBXQAU"'W#:(32ER7D*<7G5J]N)HGX<%YYM/+CFZ],_V7:^YVGK!V%ZA=H]#
MU.9''VK<W7O<>KZS,FO9CP6+!>M?6"M!5$7\8SEH;DD2C((JQC.<0E/^W]^2
M81=-/9I]F:_OQ3^139G@>N'9/3W:_ICN!U_:9:EORV5LN4>UUX]KI%M'-M14
M6,0X!N=7.Q[.N2.,AS;4)I,1) 5(/0#2'8HZ9P6)4HR5)9Y\/FNGV.8[47SN
MIZDSN;I05J/K5>=2Z#U[$73@A\Y#+G*9K6OV8S!(;'VIL/8+P4#6E'BL$6*_
M"IX=?YT^-6 X "T=,.29\P(^'"B[DFWMQVI:UG]RW;Y@^G:MI>'O>76K3M2)
MGR>JM2Z[(ZDJX>&X5L#K.@"]2.0@P,?$95()FB%*JA6OPX$&,Y-(ND<PQ\9R
M7(8:R,(2J:;WSZ/K?7WXFO2ZQZ^[R>009H?QH:K"V(EK:@[DN%[5$37S$>LZ
MT-;"P#%7+8>VRR,9B01%)$B)[H9HBW$(17CEC" 62!RV,CY0ZFX1N;:MJM=>
M2ZOYD;3+J/U=UATPZZ:KZTZ@'_A4K5U9C!F9KS3+1.S&WEN3[/<CRF,8;>L%
MOL,HE83"V\881,(.1X;;$%B-':'&VY-MZLI(]%ZK9^['J<]I;\.UP\_0M<;=
MW[L\<5)AR$>%,J6HPL[3>F9S4R7'1'2MJ8[K<I&;;6Y[)BX985E.$O)BUNC>
M34<%1R;=+5.K?B?XY,SB[D^H,ZE[0L.SNO>[O%C=^S.NZ)L*ZU$06N**R9"'
M45L\1KL6\5:,7HA&?5I)R'!;)CIPHBR7'L2FFVB67&_MRM;KNBD<.2IJ44ZO
M^IIKD\NZ*RIS537:WO/J3'BLZA=C.L#QBP4AT17"5HMFQ,ZVV'&M;\F1LD1=
MGPL8G2*-7('Z8S,>LEA*-@GA1<BDO"%N1!L)D]FO?Y1M=0?CE&6OGRX7VLF9
M]2$,O7;[RV=5.I-1$V2<& 533FJG"$(1/DP!M\W[LEV2<(YFM1G($=MNIDM>
MO25N*PB/^$ZY)7AE.,-S:TO/8IA-1A*5J\\F]E:Y\>%]S*[U5'0_>NR /53>
MF@]86C8.L](TFWZKO-=H(,C8R>O!3TNO$Z?8':^(8FE%5:1$A%1)4TS$5! .
MBA""K[*"L5>!&#)*TW5TU?I\U.C5[U6T^O\ 7:LZKHO1J[N]E:[KD+0AJ9%H
M1*UQ#MH:OQ0$:QH P*UFY3Q;4V,V712,QX$I;7L!5:D?W-9#^'.W-5>O%KTN
M\OE'Q^GPZ.;\ZQH[:>6+MYK^XTQT1HS9\W7%<V$&(!+Y=?O3G9VS=F2ZW/C1
M#HF).BU2*!K,N9"9<L[=FL<Z!%R/CC9Q ,62EX81=I5IGGHDGR7/CKD=-])S
MI*[6SM9W-[8;(!FXQL/KP/2FBMA%31ZRMGWA>Y=YM!*!^>PU]TR.WK%")[S'
MR<BL6%#+BDH(>SBT]'9.,U48IVM>V2]6=#]0R$N?<_S.=8.IE>"V296*\%T'
MI:?-A"R3PP99=W[!58[2;62:CJB1&H]-M=+7/?4ZE$-D.J0^ZE*58;B^%ZZ;
D]?BRXC#:CARE:O.ET5+NR\__ $1U#_Z;T_\ ]CA?_5R3G/_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
